Cargando…
Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
Current cancer immunotherapy has limited response rates in a large variety of solid tumors partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor microenvironment (ITM). A number of clinical cancer treatment modalities, including radiotherapy, chemotherapy, photother...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470797/ https://www.ncbi.nlm.nih.gov/pubmed/32317755 http://dx.doi.org/10.1038/s41401-020-0400-z |